The story of Natrecor highlights the enormous impact of the placebo effect, the power the expectation improvement to influence patients subjectiveassessment of symptoms.
Obviously, an unblinded trial design (also known as an open-label trial) represents a particularly high-risk approach when the outcome involves a subjectiveassessment by either the patient or the physician.